Skip to main content

Table 2 Characteristics of pSS patients with or without OA

From: Osteoarthritis or arthritis? Toward understanding of primary Sjögren’s syndrome patients with arthralgia

Variable

pSS-OA

pSS-nOA

p value1

OR

p value2

n = 186

n = 182

Female (n, %)

172(92.5)

166(91.2)

0.659

  

Age (≥ 65 year) (n, %)

71(38.2)

41(22.5)

0.001

1.965

0.009

Disease duration (year) M (IQR)

5(2–10)

3(1–10)

0.034

1.023

0.112

Clinical manifestation (n, %)

     

 Dry mouth

164(88.2)

150(82.4)

0.119

  

 Dry eye

134(72.8)

121(66.9)

0.215

  

 Mouth ulcers

52(28.0)

37(20.3)

0.088

  

 Dental caries and dentures

114(61.3)

102(56.0)

0.308

  

 Swollen parotid gland

20(10.8)

20(11.0)

0.942

  

 Rash

34(18.3)

45(24.7)

0.133

  

 Renault phenomenon

22(11.8)

32(17.6)

0.119

  

 Joint pain

108(58.1)

54(29.7)

 < 0.001

3.382

 < 0.001

 Fatigue

35(18.8)

43(23.6)

0.260

  

 ESSDAI score M (IQR)

4(2–8)

5(3–10)

0.006

0.965

0.098

ESSDAI domains (n, %)

     

 Constitutional

1(0.5)

1(0.5)

1.000

  

 Lymphadenopathy

8(4.3)

11(6.0)

0.451

  

 Glandular

22(11.8)

17(9.4)

0.461

  

 Articular

24(12.9)

17(9.4)

0.279

  

 Cutaneous

5(2.7)

13(7.1)

0.048

0.359

0.057

 Pulmonary

35(18.8)

42(23.5)

0.278

  

 Renal

7(3.8)

6(3.4)

0.833

  

 Muscular

4(2.2)

3(1.6)

1.000

  

 Peripheral nervous system

6(3.2)

11(6.0)

0.199

  

 Central nervous system

0(0.0)

1(0.5)

0.495

  

 Hematological

109(58.6)

123(67.6)

0.075

  

 Biological

103(55.7)

114(64.8)

0.078

  

Laboratory data

     

 Hemoglobin (g/L), x ± s

119 ± 14.8

115 ± 18.8

0.030

1.005

0.515

 A/G

1.3 ± 0.3

1.2 ± 0.3

0.012

0.847

0.796

 Globulin (g/L), x ± s

31.8 ± 7.5

34.5 ± 11.0

0.008

0.958

0.128

 Albumin (g/L), x ± s

38.2 ± 6.0

37.1 ± 5.1

0.058

  

 K+ (mmol/L), x ± s

3.8 ± 0.3

3.7 ± 0.4

0.015

1.404

0.263

 Uric acid (umol/L), M (IQR)

276(234.7–328.3)

261(218.0–317.0)

0.030

1.002

0.104

 TC (mmol/L), M (IQR)

4.6(4.0–5.3)

4.5(3.7–4.9)

0.025

1.015

0.670

 TG (mmol/L), M (IQR)

1.3(0.9–1.7)

1.3(0.9–1.4)

0.287

  

 HDL (mmol/L), M (IQR)

1.2(1.0–1.4)

1.2(0.9–1.3)

0.064

  

 FBG (mmol/L), x ± s

5.0 ± 1.0

4.9 ± 1.0

0.537

  

 C3 (g/L), x ± s

1.0 ± 0.2

0.9 ± 0.2

0.256

  

 C4 (g/L), x ± s

0.2 ± 0.1

0.19 ± 0.1

0.004

4.213

0.430

 ANA positive (n, %)

113(61.1)

131(72.0)

0.027

0.676

0.120

 Anti-SSA positive (n, %)

107(57.8)

123(67.6)

0.054

  

 Anti-SSB positive (n, %)

48(25.9)

53(29.1)

0.497

  

 Anti-CCP positive (n, %)

5(3.1)

4(2.8)

0.868

  

 Increased RF (n, %)

38(22.9)

45(28.3)

0.265

  

 IgA (g/L), x ± s

2.9 ± 1.4

3.3 ± 2.9

0.049

0.894

0.060

 IgM (g/L), x ± s

1.4 ± 1.4

1.6 ± 2.2

0.444

  

 IgG (g/L), x ± s

15.5 ± 6.0

16.7 ± 7.2

0.035

1.029

0.357

 IgG4 (g/L), x ± s

0.6 ± 1.8

0.5 ± 0.8

0.696

  

 Increased CRP (n, %)

15(8.3)

23(13.3)

0.133

  

 Increased ESR (n, %)

51(28.3)

60(36.1)

0.121

  

 Decreased 25-(OH)D (n, %)

28(17.5)

18(12.5)

0.226

  
  1. OA: osteoarthritis; A/G: albumin/globulin; UA: uric acid; TC: total cholesterol; TG: triglycerides; HDL: high density lipoprotein; FBG: fasting blood glucose; C3: complement 3; C4: complement 4; ANA: antinuclear antibodies; CCP: cyclic citrullinated peptide; RF: rheumatoid factor; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; 25-(OH) D: 25-hydroxy vitamin D